Vident Advisory, LLC Krystal Biotech, Inc. Transaction History
Vident Advisory, LLC
- $3.97 Trillion
- Q3 2024
A detailed history of Vident Advisory, LLC transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Vident Advisory, LLC holds 2,575 shares of KRYS stock, worth $413,261. This represents 0.01% of its overall portfolio holdings.
Number of Shares
2,575
Previous 1,965
31.04%
Holding current value
$413,261
Previous $361 Million
29.88%
% of portfolio
0.01%
Previous 0.01%
Shares
3 transactions
Others Institutions Holding KRYS
# of Institutions
310Shares Held
24.3MCall Options Held
483KPut Options Held
364K-
Black Rock Inc. New York, NY3.95MShares$634 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.85MShares$457 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.62MShares$421 Million7.18% of portfolio
-
State Street Corp Boston, MA1.45MShares$233 Million0.01% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA988KShares$159 Million9.67% of portfolio
About Krystal Biotech, Inc.
- Ticker KRYS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,664,300
- Market Cap $4.12B
- Description
- Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...